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Copaiba oil obtained from the trees of the Copaifera genus is
composed of a mixture of sesquiterpenes and diterpenes.1 More
than 75% of the composition of Copaiba oil was found to be
sesquiterpenes. It has been used as a traditional medicine for
wound healing and general inflammation.1–4 In recent years, stud-
ies of Copaiba oil and its components have revealed their potential
anti-cancer activity. The Copaiba oil from C. multijuga species and
its fraction have been reported to inhibit tumor growth in mice.5
Interestingly, a recent study by Feiella et al. revealed that hard-
wickiic acid, one of the diterpenoid acids existing in Copaiba oil,
is an inhibitor of heat shock protein 27 kD (HSP27).6
The discovery of the HSP27 inhibition by hardwickiic acid raised
our interest in the other diterpene components in Copaiba oil.6 We
speculate that other diterpenoid acids in Copaiba oil might inter-
fere with this small chaperone protein as well since the diterpene
components share similar structures. Further isolation of the indi-
vidual components in the active sub-fractions followed by struc-
tural elucidation and biological activity examination led to the
identification of two new small molecule chaperone inhibitors
including copalic acid and 3-acetoxycopalic acid (Fig. 1). All three
compounds inhibited the chaperone activity of HSP27 and a-crys-
tallin that shares a very similar structure with HSP27, suggesting
that they are small chaperone protein inhibitors.7
The over-expression of small chaperone protein HSP27 in can-
cer tissues is correlated with anti-cancer drug resistance, which
makes it a promising molecular target for drug development.8–11
HSP27 directly interacts with its client proteins affecting multiple
steps in apoptosis, including cytochrome c release, formation of
apoptosome complex, and caspase-activation.8,10,12,13 Androgen
receptor (AR) was reported to be one of the client proteins, and
knockdown of HSP27 with antisense oligonucleotides (ASO) or
siRNA could decrease AR level in prostate cancer cells.14 It has been
well-documented that AR contributes to the development and pro-
gression of prostate cancer. Based on this discovery, a clinical trial
was organized to examine the effect of HSP27 ASO OGX-427 for
prostate cancer treatment, and the result was positive and promis-
ing.15 However, this strategy is associated with difficulties in drug
delivery. It will be more desirable if small molecules that can
down-regulate AR via the inhibition of small chaperone protein
can be developed because of the higher bioavailability of small
molecules compared to ASO. Nevertheless, down-regulating AR
via small chaperone inhibitors seems to be a novel strategy for
prostate cancer treatment.
Based on this hypothesis, developing more potent small chaper-
one inhibitors is the key, and AR protein level could be used to
evaluate the potency of the compounds as well. However, the
in vitro chaperone inhibition assay has low sensitivity. Therefore,
we focus on AR as the readout to establish a screening assay for
the small chaperone inhibitor development. Although it has been
reported in other studies that HSP27 inhibition with ASO or siRNA
could lead to the degradation of AR,14 the effect of small molecule
HSP27 inhibitors to AR protein level is still unclear. All three com-
pounds in Fig. 1 showed direct inhibition of HSP27 and a-crys-
tallin, and they are different to the ASO or siRNA strategies.7 We
hypothesize that these small chaperone inhibitors may also induce
AR degradation. The AR protein level was determined after the
treatment of LNCaP prostate cancer cells with these three natural
products. The results exhibited that the small chaperone inhibitors
could decrease the AR level in prostate cancer cells (Fig. 2). Copalic
acid and 3-acetoxycopalic acid seem to show better activity com-
pared to hardwickiic acid. Suppressing AR via targeting the chaper-
one protein with the small molecule inhibitor could be a novel
approach in prostate cancer treatment or prevention.
In Copaiba oil, the abundance of copalic acid is much higher
compared to the other diterpenoid acids. It was also more potent
than hardwickiic acid and 3-acetoxycopalic acid in inhibiting small
chaperone protein in our previous study,7 and more potent in
downregulating AR in prostate cancer cells as well (Fig. 2). All
the results make copalic acid a better lead compound for the devel-
opment of potential drug candidates to down-regulate AR. Herein,
a series of copalic acid derivatives were designed and synthesized
in order to improve its potency to down-regulate AR.
Following the procedure of the isolation of copalic acid in our
previous study, about 500 mg copalic acid was isolated and puri-
fied.7 Then the carboxylic acid moiety of the compound was mod-
ified to different amide or ester analogs as indicated in Fig. 3.
Different substituent groups were linked to copalic acid at the car-
boxyl group via a one-step reaction with dicyclohexylcarbodiimide
(DCC). In general, 30 mg (0.1 mmol) of copalic acid, 62 mg of DCC
(0.3 mmol), and 0.15 mmol of aromatic amine or phenol were stir-
red at room temperature in dichloromethane until the copalic acid
was nearly fully consumed. The insoluble solid was filtered, and
the solid was washed with dichloromethane. The filtrate was con-
centrated under vacuum and the residue was purified by column
chromatograph to yield the product. A compound library of 15
copalic acid analogs was developed.
The compounds were examined for their activity to down-reg-
ulate AR in LNCaP cancer cells. For the testing, 200 mM copalic acid
was used as a positive control since 20 mM copalic acid did not
show any activity to decrease AR (data not shown). The results
revealed that the modification of the carboxylic acid moiety gener-
ally increased the activity of some analogs. At 20 mM, compounds
3, 5, 12, and 13 showed moderate activity to decrease the AR level,
which is better than copalic acid. Compounds 4 and 7 seem to abol-
ish all the AR in the cells at 20 mM. The results suggest that the aro-
matic moiety may promote the activity (Fig. 4). It is possible that
the conversion of carboxylic acid moiety may enhance the penetra-
tion of the compounds into the cells, because the carboxylic acid
group is ionized in the cell culture medium, and the generated neg-
ative charge limits the capability of copalic acid to penetrate the
cell membrane. Considering some of the analogs showed improved
activity, it is very likely that at least the changes to hydrophobicity
contribute to this increased activity. Compounds 4 and 7 showed
the best activity, but their aromatic ring structure cannot provide
enough information to summarize what type of substituents on
the phenyl ring might improve the activity. Subsequently, a
dose-dependent experiment was performed to further examine
the two compounds. The results exhibited their dose-dependent
activity in LNCaP cells to suppress AR protein level. Particularly,
compound 4 at 5 mM dramatically decreased AR in the cells. In
addition, compounds 4 and 7 showed IC50s of 1.73 ± 0.72 mM and
9.81 ± 0.92 mM, respectively, to inhibit the growth of LNCaP cells,
suggesting that they have the potential to be the hit compounds
for further drug development to treat prostate cancer (Fig. 5).
Finally, the chaperone inhibition of the compounds was investi-
gated with an in vitro chaperone assay. a-Crystallin could stabilize
dithiothreitol (DTT) induced insulin precipitation, and the chaper-
one function was inhibited by copalic acid, hardwickiic acid, and
3-acetoxycopalic acid in our previous study.7,16 Compounds 4
and 7 showed a clear inhibition of the chaperone function of
a-crystallin, suggesting that the two compounds are small chaper-
one inhibitors (Fig. 6). They showed better potency than the lead
compound copalic acid in down-regulating AR and inhibiting can-
cer cell growth.
In summary, we lead optimized copalic acid in order to develop
more potent AR down-regulating agents in prostate cancer cells. It
has been well documented that AR still plays a critical role in pros-
tate cancer even after the patients developed resistance to andro-
gen receptor blocking agents.14 Down-regulating AR has been
proposed as a new strategy for the endocrine therapy resistant
prostate cancer treatment.8 Using small chaperone inhibitor to tar-
get AR has showed promising results in the clinical trial. However,
Fig. 1. Structures of copalic acid, hardwickiic acid, and 3-acetoxycopalic acid.
Fig. 2. Effects of copalic acid (CA) and hardwickiic acid (HA) and 3-acetoxycopalic
acid (ACA) on the protein level of AR. LNCaP cells were treated with DMSO, three
diterpenoid acids (200 mM) for 48 h. Levels of AR and b-actin were analyzed by
Western blotting of cell extracts with specific antibodies. The experiment was
repeated independently for three times and the representative one is presented.
Fig. 3. Synthesis of the copalic acid analogs.
Fig. 4. Effects of the copalic acid analogs on the protein level of AR. LNCaP cells were treated with DMSO, copalic acid (200 mM) and all the analogs (20 mM) for 48 h. Levels of
AR and b-actin were analyzed by Western blotting of cell extracts with specific antibodies. The results are from three independent experiments and a representative one is
presented. (A) the screening of all the analogs; (B) dose dependent activity of compound 4; (C) dose dependent activity of compound 7.
these strategies rely on ASO or siRNA to knockdown the small
chaperone protein, and then decrease AR level. Our findings indi-
cate that small molecule inhibitors have the capability to decrease
AR level just like ASO or siRNA. We identified two small chaperone
inhibitors that showed promising activity to down-regulate AR and
inhibit prostate cancer cell growth, which supports our hypothesis
that targeting AR with small molecule chaperone inhibitor is an
effective approach for prostate cancer treatment or prevention.
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